Content area

Full text

Qing Shi [1] and Rong Shen [1] and Chao-Fu Wang [2] and Xing Fan [1] and Ying Qian [1] and Bin-Shen Ou-Yang [2] and Yan Zhao [1] and Christophe Leboeuf [3; 4] and Anne Janin [3; 4] and Shu Cheng [1] and Li Wang [1; 3] and Wei-Li Zhao [1; 3]

Academic Editor: Dechun Feng

1, , State Key Laboratory of Medical Genomics, , Shanghai Institute of Hematology, , Shanghai Rui Jin Hospital, , Shanghai Jiao Tong University School of Medicine, , Shanghai, , China, shsmu.edu.cn

2, , Department of Pathology, , Shanghai Rui Jin Hospital, , Shanghai Jiao Tong University School of Medicine, , Shanghai, , China, shsmu.edu.cn

3, , Pôle de Recherches Sino-Français en Science du Vivant et Génomique, , Shanghai Rui Jin Hospital, , Shanghai Jiao Tong University School of Medicine, , Shanghai, , China, shsmu.edu.cn

4, , U1165 Inserm/Université Paris 7 and Hôpital Saint Louis, , Paris, , France, univ-paris-diderot.fr

Received Jul 6, 2017; Accepted Aug 17, 2017

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) [1], while displaying great heterogeneity in clinical manifestation, disease course, and prognosis. The International Prognostic Index (IPI), based on age, performance status, lactate dehydrogenase (LDH), Ann Arbor stage, and extranodal involvements, was originally designed for prediction of prognosis in aggressive lymphoma during the prerituximab era [2]. Although already proven, in a cohort of 2031 patients, it is helpful to stratify DLBCL patients into low-, low-intermediate-, high-intermediate-, and high-risk groups, with 5-year overall survival (OS) rates of 73%, 51%, 43%, and 26%, respectively [2]. Recently, the revised IPI (R-IPI) and National Comprehensive Cancer Network IPI (NCCN-IPI) appear to better predict prognosis in DLBCL patients. The R-IPI identifies three distinct prognostic groups with outcomes categorized as very good (patients with no IPI risk factors, 4-year OS 94%), good (patients with 1 or 2 risk factors, 4-year OS 79%), and poor (patients with 3–5 risk factors, 4-year OS 55%), respectively [3]. The NCCN-IPI is based on five predictors (age, LDH, extranodal sites, Ann Arbor stage, and performance status) and 4...
 

Show less